Skip to content
sdatbusiness

sdatbusiness

Business management

Primary Menu sdatbusiness

sdatbusiness

  • Business management
  • Advertise Here
  • Contact Us
  • Privacy Policy
  • Sitemap
  • business & finance

UNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business Updates

2 weeks ago Magenet Magenet


Unity Biotechnology, Inc.

Unity Biotechnology, Inc.

-Completed enrollment in BEHOLD, the Phase 2 clinical trial of UBX1325 in DME; BEHOLD remains on track with 12-week safety and efficacy data anticipated by mid-year 2022-

-Dosed first patient in ENVISION, the Phase 2 clinical trial of UBX1325 in wet age-related macular degeneration; ENVISION remains on track with 16-week results expected in Q4 2022-

Related Posts:

  • Allegion to Acquire Stanley Black & Decker’s Access Technologies Business

-As of March 31, 2022, UNITY had approximately $79.2 million in cash, cash equivalents and marketable securities, extending runway through Q1 2023-

SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2022.

“The outset of 2022 was marked by important progress across our ongoing clinical development program for UBX1325, such as successfully completing enrollment for BEHOLD, our Phase 2 clinical trial of UBX1325 in patients with diabetic macular edema (DME), as well as initiating ENVISION, our Phase 2 clinical trial of UBX1325 in patients with wet age-related macular degeneration (wAMD),” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “We are encouraged by the growing evidence that underscores the role cellular senescence plays in ocular diseases, and believe we are well positioned to build on the results from the promising Phase 1 trial of UBX1325, which we recently presented at the ARVO 2022 Annual Meeting. Looking ahead, we remain on track to deliver on multiple upcoming catalysts, including 12-week data from our DME study by mid-year 2022. We are appreciative of the support and the enthusiasm we have received from patients and KOLs, and we will continue to deliver on our mission to address the urgent need for innovative therapeutic alternatives beyond anti-VEGFs for key ophthalmologic conditions.”

Upcoming Milestones

  • UBX1325 12-week safety and efficacy data from BEHOLD, the Phase 2a DME clinical trial (UBX1325-02 Study) by mid-year 2022, as well as 24-week safety and efficacy data before year-end 2022

  • UBX1325 16-week safety and efficacy data from ENVISION, the Phase 2 wAMD clinical trial (UBX1325-03 Study) expected in Q4 2022

  • Tie2/VEGF bispecific preclinical data to support selection of advanced candidate by mid-year 2022

First Quarter Financial Results

Cash, cash equivalents and marketable securities totaled $79.2 million as of March 31, 2022, compared with $90.1 million as of December 31, 2021. UNITY believes that current cash, cash equivalents, and marketable securities are sufficient to fund operations through the first quarter of 2023.

Operating loss for the three months ended March 31, 2022, was $18.9 million compared to $15.8 million for the three months ended March 31, 2021. Cash used in operations during the first quarter of 2022 was $15.0 million compared to $15.1 million for the first quarter of 2021.

Research and development expenses increased by $3.8 million, to $12.5 million for the three months ended March 31, 2022, from $8.7 million for the three months ended March 31, 2021. The increase was primarily due to increases of $3.5 million in direct research and development expenses mainly due to the progress of UBX1325 studies and $1.2 million in personnel costs due to reduction in force and $0.4 million in retention bonus accruals, offset by decreases of $0.7 million in facilities-related costs due to allocation to general and administrative expenses of net expenses on Brisbane and East Grand facilities which have been subleased, $0.2 million in employee stock based compensation forfeited from the reduction in force and $0.4 million in laboratory supplies.

General and administrative expenses decreased by $0.4 million, to $5.8 million for the three months ended March 31, 2022, from $6.2 million for the three months ended March 31, 2021. The decrease was primarily due to decreases of $0.6 million in facilities-related costs, $0.3 million in recruitment expenses and $0.2 million in professional fees, offset by increases of $0.4 in personnel costs mainly due to reduction in force and $0.2 million in retention bonus accruals and $0.1 million in insurance expense.

About UNITY

UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to slow, halt, or reverse diseases of aging, including for ophthalmologic and neurologic diseases, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for DME, AMD, and other ophthalmologic diseases, the expected timing of enrollment and results of the clinical trials in UBX1325, and UNITY’s expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials, risks relating to the uncertainties inherent in the drug development process, and risks relating to UNITY’s understanding of senescence biology. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of UNITY in general, see UNITY’s most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed with the Securities and Exchange Commission on May 10, 2022, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.

Unity Biotechnology, Inc.
Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)

Three Months Ended

March 31,

2022

2021

(Unaudited)

Operating expenses:

Research and development

12,461

8,717

General and administrative

5,806

6,226

Total operating expenses

18,267

14,943

Loss from operations

(18,267

)

(14,943

)

Interest income

29

36

Interest expense

(808

)

(775

)

Other income (expense), net

131

(74

)

Net loss

(18,915

)

(15,756

)

Other comprehensive (loss) gain

Unrealized (loss) gain on marketable debt securities

(132

)

10

Comprehensive loss

$

(19,047

)

$

(15,746

)

Net loss per share, basic and diluted

$

(0.28

)

$

(0.29

)

Weighted-average number of shares used in
computing net loss per share, basic and
diluted

67,528,552

54,169,349

Unity Biotechnology, Inc.
Condensed Balance Sheets
(In thousands)

March 31,

December 31,

2022

2021

(Unaudited)

Assets

Current Assets:

Cash and cash equivalents

$

16,446

$

32,905

Short-term marketable securities

62,717

55,170

Prepaid expenses and other current assets

1,770

1,879

Restricted cash

550

550

Total current assets

81,483

90,504

Property and equipment, net

9,308

9,942

Operating lease right-of-use assets

20,706

21,286

Long-term marketable securities

—

1,993

Long-term restricted cash

896

896

Other long-term assets

76

91

Total assets

$

112,469

$

124,712

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$

3,323

$

1,985

Accrued compensation

2,837

4,028

Accrued and other current liabilities

6,692

6,370

Deferred revenue

216

216

Derivative liability related to debt

—

963

Current portion of long-term debt

4,837

3,055

Total current liabilities

17,905

16,617

Operating lease liability, net of current portion

29,339

30,094

Long-term debt, net

14,534

18,409

Other long-term liabilities

—

23

Total liabilities

61,778

65,143

Commitments and contingencies

Stockholders’ equity:

Common stock

7

6

Additional paid-in capital

469,799

459,631

Accumulated other comprehensive loss

(176

)

(44

)

Accumulated deficit

(418,939

)

(400,024

)

Total stockholders’ equity

50,691

59,569

Total liabilities and stockholders’ equity

$

112,469

$

124,712

CONTACT: Media Canale Communications Jason Spark [email protected] Investor Contact LifeSci Advisors, LLC Joyce Allaire [email protected]



Source link

Tags: "Women'S Business Casual, Amazon Fba Business, Atlanta Business Chronicle'S, Boss Baby Back In Business, Business Administration Degree, Business Attire Women, Business Card Design, Business Cards Templates, Business Casual Dress, Business Casual Outfits, Business Checking Account, Business Credit Card, Business For Sale Near Me, Business Intelligence Platform, Business Lawyer Near Me, Business Loan Calculator, Business Name Ideas, Business Professional Women, Business Spectrum Login, California Business Entity Search, Capital One Spark Business, Carl Weber'S The Family Business, Charlotte Business Journal, Custom Business Cards, Delaware Business Search, Fl Sos Business Search, Florida Business Search, Harvard Business Publishing, Insurance For Small Business, Kelley School Of Business, Maryland Business Express, Maryland Business Search", Moo Business Cards, National Business Furniture, New York Business Search, Ohio Business Gateway, Onedrive For Business, Online Business Ideas, Paramore Misery Business, Risky Business Cast, Small Business Insurance, Spectrum Business Customer Service, Tom Cruise Risky Business, Us Small Business Administration, Verizon Wireless Business, Verizon Wireless Business Login, Virtual Business Address, What Is Business Administration, Yelp Business Login, Yelp For Business

Continue Reading

Previous Will Your Social Security Check Be Bigger Than the $4,194 Max Benefit? | Personal-finance
Next Where Finance of America Stands With Analysts

More Stories

  • business & finance

South Africa US$765.9 Million Embedded Finance Business and Investment Market to 2029: A $3,091.1 million Opportunity | News

7 hours ago Magenet Magenet
  • business & finance

Signature Bank Launches New National Business Line With Appointment of Healthcare Banking and Finance Team | National Business

2 days ago Magenet Magenet
  • business & finance

Signature Bank Launches Healthcare Banking and Finance Business Line

3 days ago Magenet Magenet

Recent Posts

  • Visual Content Marketing on Social Media 
  • ‘Akhanda’ movie review: Boyapati Srinu and Nandamuri Balakrishna’s loud action entertainer is strictly for the fanbase
  • Workers’ advocates turned away at Dollar General meeting
  • British power firms’ shares slide after windfall tax report
  • Russia Excluded From Global Banking?

Archives

  • May 2022
  • April 2022
  • March 2022
  • January 2022
  • December 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • December 2020
  • November 2020
  • November 2018
  • October 2018
  • January 2017

Categories

  • business
  • business
  • business & finance
  • Business management
  • finance
  • General


09c4b4c6a4381ca6a3af449163783335a47073bc 

Business

travel trailers for sale

visit now

technology colleges
Intellifluence Trusted Blogger

backlinks

linkspanel

textlinks

You may have missed

  • General

Visual Content Marketing on Social Media 

4 hours ago Magenet Magenet
  • General

‘Akhanda’ movie review: Boyapati Srinu and Nandamuri Balakrishna’s loud action entertainer is strictly for the fanbase

4 hours ago Magenet Magenet
  • General

Workers’ advocates turned away at Dollar General meeting

4 hours ago Magenet Magenet
  • finance

British power firms’ shares slide after windfall tax report

5 hours ago Magenet Magenet
  • finance

Russia Excluded From Global Banking?

6 hours ago Magenet Magenet
sdatbusiness.xyz All rights reserved. | CoverNews by AF themes.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT